The latest report by IMARC Group, titled “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. offers a comprehensive analysis of the industry, which comprises insights on the global hyperlipidemia drugs market share. The global market size reached US$ 22.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 25.2 Billion by 2028, exhibiting a growth rate (CAGR) of 1.8% during 2023-2028.

The term "hyperlipidemia" describes a medical disorder in which the blood's lipid or fat levels are unusually elevated. This is a prevalent kind of dyslipidemia that can be inherited or brought on by an unhealthful food and way of living. Obesity, hypertension, cardiac stroke, peripheral vascular illnesses, and cardiovascular disorders (CVDs) are all possible outcomes of the ailment. Lipid panel or lipid profile blood tests are used to identify hyperlipidemia. The first line of treatment for secondary hyperlipidemia brought on by an unhealthy lifestyle is statins. Other often prescribed medications for the management of hyperlipidemia include PCSK9, bile acid sequestrants, and several antihyperlipidemic medicines that aid in lowering hepatic cholesterol synthesis. They also lessen inflammation and cell damage, as well as the quantity of lipids in the blood.

Request Your Sample Report Now: https://www.imarcgroup.com/hyperlipidemia-drugs-market/requestsample

Hyperlipidemia Drugs Market Trends and Drivers:

The market for medications for hyperlipidemia in the world is mainly driven by rising awareness of the hazards of high cholesterol and CVDs. To reduce the risk of these disorders, governments are advocating the use of anti-hyperlipidemic medications and revising the categories of patients who are considered to be at-risk. Furthermore, the impending patent expiration has led to the genericization of cholesterol absorption inhibitors and statins, which is greatly accelerating the market's growth. Additionally, the global market is being positively impacted by the introduction of novel products, such as the development of medications with improved efficacy and safety profiles. In addition, a great deal of research and development (R&D) has been done to create novel medications.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Drug Type:

• Statins
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• Others

Breakup by End User:

• Hospitals
• Clinics
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• Amgen Inc.
• AstraZeneca PLC
• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• Esperion Therapeutics Inc.
• GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
• Immuron Limited
• Ionis Pharmaceuticals Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• Sanofi S.A.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal